Vectura, Inspira team up to develop inhaled COVID-19 drug
7th May 2021
Contract development and manufacturing organisation (CDM) Vectura Group and Inspira Pharmaceuticals, a new UK-based company focused on developing therapies for respiratory and infectious diseases, have teamed up to develop an inhaled formulation of the latter s lead drug candidate for the treatment of COVID-19.
Inspira’s research focuses on proprietary IPX formulations, which are based on processed and purified extracts from a plant source. These extracts contain proteolytic enzymes that have been shown to rapidly inactivate the SARS-CoV-2 virus in vitro. The IPX technology platform has additional potential applications in other lung infections and treatment of biofilms associated with respiratory disease.